Cargando…

UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma

CONTEXT: Sibiricose A5 (A5), sibiricose A6 (A6), 3,6′-disinapoyl sucrose (DSS), tenuifoliside A (TFSA) and 3,4,5-trimethoxycinnamic acid (TMCA) are the main active components of Polygala tenuifolia Willd. (Polygalaceae) (PT) that are active against Alzheimer's disease. OBJECTIVE: To compare the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xin, Xu, Baoxin, Wu, Peng, Zhao, Pan, Guo, Changchuan, Cui, Yueli, Zhang, Yanxue, Zhang, Xuelan, Li, Huifen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534330/
https://www.ncbi.nlm.nih.gov/pubmed/32956609
http://dx.doi.org/10.1080/13880209.2020.1818790
_version_ 1783590294958112768
author Zhao, Xin
Xu, Baoxin
Wu, Peng
Zhao, Pan
Guo, Changchuan
Cui, Yueli
Zhang, Yanxue
Zhang, Xuelan
Li, Huifen
author_facet Zhao, Xin
Xu, Baoxin
Wu, Peng
Zhao, Pan
Guo, Changchuan
Cui, Yueli
Zhang, Yanxue
Zhang, Xuelan
Li, Huifen
author_sort Zhao, Xin
collection PubMed
description CONTEXT: Sibiricose A5 (A5), sibiricose A6 (A6), 3,6′-disinapoyl sucrose (DSS), tenuifoliside A (TFSA) and 3,4,5-trimethoxycinnamic acid (TMCA) are the main active components of Polygala tenuifolia Willd. (Polygalaceae) (PT) that are active against Alzheimer's disease. OBJECTIVE: To compare the pharmacokinetics and bioavailability of five active components in the roots of raw PT (RPT), liquorice-boiled PT (LPT) and honey-stir-baked PT (HPT). MATERIALS AND METHODS: The median lethal dose (LD(50)) was evaluated through acute toxicity test. The pharmacokinetics of five components after oral administration of extracts of RPT, LPT, HPT (all equivalent to 1.9 g/kg of RPT extract for one dose) and 0.5% CMC-Na solution (control group) were investigated, respectively, in Sprague-Dawley rats (four groups, n = 6) using UHPLC-MS/MS. In addition, the absolute bioavailability of A5, A6, DSS, TFSA and TMCA after oral administration (7.40, 11.60, 16.00, 50.00 and 3.11 mg/kg, respectively) and intravenous injection (1/10 of the corresponding oral dose) in rats (n = 6) was studied. RESULTS: The LD(50) of RPT, LPT and HPT was 7.79, 14.55 and 15.99 g/kg, respectively. AUC(0-)(t) of RPT, LPT and HPT were as follows: A5 (433.18 ± 65.48, 680.40 ± 89.21, 552.02 ± 31.10 ng h/mL), A6 (314.55 ± 62.73, 545.76 ± 123.16, 570.06 ± 178.93 ng h/mL) and DSS (100.30 ± 62.44, 232.00 ± 66.08, 197.58 ± 57.37 ng h/mL). The absolute bioavailability of A5, A6, DSS, TFSA and TMCA was 3.25, 2.95, 2.36, 1.17 and 42.91%, respectively. DISCUSSION AND CONCLUSIONS: The pharmacokinetic and bioavailability parameters of each compound can facilitate future clinical studies.
format Online
Article
Text
id pubmed-7534330
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75343302020-10-14 UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma Zhao, Xin Xu, Baoxin Wu, Peng Zhao, Pan Guo, Changchuan Cui, Yueli Zhang, Yanxue Zhang, Xuelan Li, Huifen Pharm Biol Research Article CONTEXT: Sibiricose A5 (A5), sibiricose A6 (A6), 3,6′-disinapoyl sucrose (DSS), tenuifoliside A (TFSA) and 3,4,5-trimethoxycinnamic acid (TMCA) are the main active components of Polygala tenuifolia Willd. (Polygalaceae) (PT) that are active against Alzheimer's disease. OBJECTIVE: To compare the pharmacokinetics and bioavailability of five active components in the roots of raw PT (RPT), liquorice-boiled PT (LPT) and honey-stir-baked PT (HPT). MATERIALS AND METHODS: The median lethal dose (LD(50)) was evaluated through acute toxicity test. The pharmacokinetics of five components after oral administration of extracts of RPT, LPT, HPT (all equivalent to 1.9 g/kg of RPT extract for one dose) and 0.5% CMC-Na solution (control group) were investigated, respectively, in Sprague-Dawley rats (four groups, n = 6) using UHPLC-MS/MS. In addition, the absolute bioavailability of A5, A6, DSS, TFSA and TMCA after oral administration (7.40, 11.60, 16.00, 50.00 and 3.11 mg/kg, respectively) and intravenous injection (1/10 of the corresponding oral dose) in rats (n = 6) was studied. RESULTS: The LD(50) of RPT, LPT and HPT was 7.79, 14.55 and 15.99 g/kg, respectively. AUC(0-)(t) of RPT, LPT and HPT were as follows: A5 (433.18 ± 65.48, 680.40 ± 89.21, 552.02 ± 31.10 ng h/mL), A6 (314.55 ± 62.73, 545.76 ± 123.16, 570.06 ± 178.93 ng h/mL) and DSS (100.30 ± 62.44, 232.00 ± 66.08, 197.58 ± 57.37 ng h/mL). The absolute bioavailability of A5, A6, DSS, TFSA and TMCA was 3.25, 2.95, 2.36, 1.17 and 42.91%, respectively. DISCUSSION AND CONCLUSIONS: The pharmacokinetic and bioavailability parameters of each compound can facilitate future clinical studies. Taylor & Francis 2020-09-21 /pmc/articles/PMC7534330/ /pubmed/32956609 http://dx.doi.org/10.1080/13880209.2020.1818790 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhao, Xin
Xu, Baoxin
Wu, Peng
Zhao, Pan
Guo, Changchuan
Cui, Yueli
Zhang, Yanxue
Zhang, Xuelan
Li, Huifen
UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma
title UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma
title_full UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma
title_fullStr UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma
title_full_unstemmed UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma
title_short UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma
title_sort uhplc-ms/ms method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of polygala tenuifolia in rat plasma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534330/
https://www.ncbi.nlm.nih.gov/pubmed/32956609
http://dx.doi.org/10.1080/13880209.2020.1818790
work_keys_str_mv AT zhaoxin uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT xubaoxin uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT wupeng uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT zhaopan uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT guochangchuan uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT cuiyueli uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT zhangyanxue uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT zhangxuelan uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma
AT lihuifen uhplcmsmsmethodforpharmacokineticandbioavailabilitydeterminationoffivebioactivecomponentsinrawandvariousprocessedproductsofpolygalatenuifoliainratplasma